Evidence map›Paper›PMID 24991902›Full record

ArticleAIDS (London, England)2014

Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival.

Andrea L Ciaranello, Valeriane Leroy, Asinath Rusibamayila, Kenneth A Freedberg, Roger Shapiro, Barbara Engelsmann, Shahin Lockman, Kathleen A Kelly, François Dabis, Rochelle P Walensky

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Andrea L CiaranelloaMedical Practice Evaluation Center, Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA bUniversité Bordeaux, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), and Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France cDivision of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA dHarvard Center for AIDS Research, Boston, Massachusetts, USA eDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA fDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA gThe Botswana-Harvard School of Public Health, AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana hOrganization for Public Health Interventions and Development, Harare, Zimbabwe iDivision of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Valeriane Leroy
Asinath Rusibamayila
Kenneth A Freedberg
Roger Shapiro
Barbara Engelsmann
Shahin Lockman
Kathleen A Kelly
François Dabis
Rochelle P Walensky
Massachusetts General Hospital · USApple (Israel) · ILAIDS United · USBordeaux Population Health · FRBotswana Harvard AIDS Institute Partnership · BWInserm · FR

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Optimizing Outcomes for HIV-Exposed and HIV-Infected Children in South AfricaK01AI078754 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CIARANELLO, ANDREA LYNNE · 2009 to 2013
$685k
Optimal Strategies for Management of HIV DiseaseK24AI062476 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEDBERG, KENNETH ALAN · 2004 to 2008
$512k
INTRACELLULAR PH PHYSIOLOGY IN MESANGIAL CELL GROWTHF32DK009001 · NIDDK · YALE UNIVERSITY · PI SINGH, SATISH K · 1993 to 1995
–
NIAID NIH HHS K01 AI078754NIAID NIH HHS K24 AI062476NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1AI068632NICHD NIH HHS HHSN267200800001CNIDDK NIH HHS HHSN267200800001GNIDDK NIH HHS N01-DK-9-001
6 · The paper itself

Abstract

objectivesTo determine how infant feeding recommendations can maximize HIV-free survival (HFS) among HIV-exposed, uninfected African infants, balancing risks of breast milk-associated HIV infection with setting-specific risks of illness and death associated with replacement feeding.

designValidated mathematical model of HIV-exposed, uninfected infants, with published data from Africa.

methodsWe projected 24-month HFS using combinations of: maternal CD4, antiretroviral drug availability, and relative risk of mortality among replacement-fed compared to breastfed infants ('RR-RF', range 1.0-6.0). For each combination, we identified the 'optimal' breastfeeding duration (0-24 months) maximizing HFS. We compared HFS under an 'individualized' approach, based on the above parameters, to the WHO 'public health approach' (12 months breastfeeding for all HIV-infected women).

resultsProjected HFS was 65-93%. When the value of RR-RF is 1.0, replacement feeding from birth maximized HFS. At a commonly reported RR-RF value (2.0), optimal breastfeeding duration was 3-12 months, depending on maternal CD4 and antiretroviral drug availability. As the value of RR-RF increased, optimal breastfeeding duration increased. Compared to the public health approach, an individualized approach improved absolute HFS by less than 1% if RR-RF value was 2.0-4.0, by 3% if RR-RF value was 1.0 or 6.0, and by greater amounts if access to antiretroviral drugs was limited.

conclusionTailoring breastfeeding duration to maternal CD4, antiretroviral drug availability, and local replacement feeding safety can optimize HFS among HIV-exposed infants. An individualized approach leads to moderate gains in HFS, but only when mortality risks from replacement feeding are very low or very high, or antiretroviral drug availability is limited. The WHO public health approach is beneficial in most resource-limited settings.

Indexed as

Breast FeedingModels, TheoreticalAdultAfricaAnti-HIV AgentsCD4 Lymphocyte CountChild, PreschoolFemaleGuidelines as TopicHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalPregnancyWorld Health OrganizationAnti-HIV Agents

Identifiers

PMID24991902
PMCPMC4098721
OpenAlexW2045853767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.